The Investment Accelerator of the Community of Madrid has declared as a strategic project the expansion that Laboratorios ROVI will undertake at its plant in San Sebastián de los Reyes (Madrid), with which it plans to increase its current production capacity, thanks to the commissioning of a new high-speed line with a capacity of 100 million syringes.
The expansion project will involve an investment of around 60 million euros. The group has acquired adjoining land for a total area of 54,715 m2, which will increase production capacity by more than 31.5 percent to a total of 420 million prefilled syringes and 80 million vials by 2027.
To respond to the increase in activity, the group will incorporate new buildings for the expansion of production areas and new lines, a new quality laboratory and office building, and auxiliary storage and maintenance buildings, among others. The project envisages providing the industrial complex with new accesses and improving internal circulation, as well as increasing the number of parking spaces to meet the needs of the current and future workforce.
The various investments to increase the plant’s production capacity between 2023 and 2027 will create 200 new direct skilled jobs.
With this, the ROVI Group is positioned as one of the largest industrial pharmaceutical groups in Spain and among the world leaders in the production of injectables.